Clinical guidelines for diagnosing and treating chronic obstructive pulmonary disease;Guía clínica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica

Archivos de Bronconeumologia

Volumn 37, Issue 6, 2001, Pages 297-316

  Barbera J A ^a   Peces Barba, G ^b   Agusti A G N ^c   Izquierdo, J L ^d   Monso E ^e   Montemayor, T ^d,e   Viejo, J L ^f  

^a HOSPITAL CLÍNIC   (Spain)

^b Fundacion Jimenez Deaz   (Spain)

^c HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; GLUCOCORTICOID;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EXAMINATION; CLINICAL PRACTICE; HUMAN; LUNG TRANSPLANTATION; PRACTICE GUIDELINE; REVIEW; TREATMENT INDICATION;

EID: 0034940739     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2896(01)75074-0     Document Type: Article

References (183)

1. Normativa sobre diagnóstico de la enfermedad pulmonar obstructiva crónica
2. Optimal assessment and management of chronic obstructive pulmonary disease (COPD)
3. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease
4. The definition of emphysema: Report of National Heart and Blood Institute, division of Lung Diseases, workshop
5. Lung function testing: Selection of reference values and interpretative strategies
6. Guidelines for the management of chronic obstructive pulmonary disease
7. Monitoring the progression of chronic obstructive pulmonary disease: Time for a new staging system
8. 2 as predictor of health care resources utilization (HCUR)
9. Estudio IBERPOC en España: Prevalencia de síntomas respiratorios habituales y de limitación crónica al flujo aéreo
10. Underdiagnosis and geographical differences in COPD prevalence in Spain
11. Enfermedad pulmonar obstructiva crónica. Enfoque actual
12. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease
13. Site and nature of airway obstruction in chronic obstructive lung disease
14. The relations between structural changes in small airways and pulmonary function tests
15. Alveolar inflammation and its relation to emphysema in smokers
16. + T lymphocytes with FEV1
17. + T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease
18. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease
19. Predominant TH2-like broncho-alveolar T-lymphocite population in atopic asthma
20. IL-4 and IL-5 mRNA and protein in bronchial biopsies from atopic and non atopic asthma. Evidence against "intrinsic" asthma begin a distinct immunopathological entity
21. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma
22. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis
23. Collagen content of alveolar wall tissue in emphysematous and non-emphysematous lungs
24. Extracellular matrix and inflammation: A role of fibroblast-mediated tissue repair in the pathogenesis of emphysema
25. Centrilobular and panlobular emphysema in smokers. Two distinct morphologic and functional entities
26. Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease
27. Endothelial dysfunction in pulmonary arteries of patients with mild COPD
28. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease
29. Exposure to biomass smoke of chronic airway disease in Mexican women. A case-control study
30. The natural history of chronic airflow obstruction
31. The relationship between pulmonary function and dyspnea in obstructive lung disease
32. Psychophysical basis of perceived exertion
33. The measurement of dyspnea: Contents, interobserver agreement, and physiologic correlates of two new clinical indexes
34. Comparison of clinical dyspnea ratings and psychophysical measurements of respiratory sensation in obstructive airway disease
35. Physician perceptions and management of COPD
36. Weight loss in a reversible factor in the prognosis of chronic obstructive pulmonary disease
37. The acute effects of oral prednisolone in patients with COPD in the ISOLDE trial: Responders and non-responders
38. Results of 150 consecutive bilateral lung volume reduction procedures in patients with severe emphysema
39. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease
40. Responses to exercise in lung diseases
41. Peak exercise response in relation to tissue depletion in patients with chronic obstructive pulmonary disease
42. Improved exercise performance following lung volume reduction surgery for emphysema
43. Trastornos respiratorios durante el sueño en la enfermedad pulmonar obstructiva crónica
44. Breathing during sleep in patients with obstructive lung disease
45. Do sleep studies contribute to the management of patients with severe chronic obstructive pulmonary disease?
46. 2 above 60 mmHg
47. Radiographic appearance of the chest in emphysema
48. The radiographic diagnosis of emphysema
49. Identification of pulmonary hypertension in chronic obstructive pulmonary disease from routine chest radiographs
50. Higher risk of lung cancer in chronic pulmonary disease. A prospective matched case-controlled study
51. High-resolution CT diagnosis of emphysema in symptomatic patients with normal chest radiographs and isolated low diffusing capacity
52. The diagnosis of mild emphysema. Correlation of computed tomography and pathology scores
53. Quality of life in patients with chronic airflow limitation
54. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire
55. Traducción española y validación de un cuestionario de calìdad de vìda en pacìentes con enfermedad pulmonar obstructiva crónìca
56. Validity and reliability of the St. George's Respiratory Questionnaire after adaptation to a different language and culture: The Spanish example
57. Health status in chronic obstructive pulmonary disease
58. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: The Lung Health Study
59. Normativa para el tratamiento del tabaquìsmo
60. Meta-analysis of efficacy of nicotine replacement therapies in smoking cessation
61. Nicotine nasal spray with nicotine patch for smoking cessation: Randomised trial with six year follow up
62. A comparison of sustained-release bupropion and placebo for smoking cessation
63. A controlled trial of sustained bupropion, a nicotine patch, or both for smoking cessation
64. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community
65. Randomized trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people
66. OM-85 for COPD
67. Bronchodilator reversibility, exercise performance and brethlessness in stable obstructive pulmonary disease
68. Evaluación de la respuesta broncodilatadora con agonistas beta en pacientes con enfermedad pulmonar obstructiva crónica
69. New developments in anticholinergic drugs
70. Routine nebulized ipratropium and albuterol together are better than either alone in COPD
71. Should long acting beta-2-agonist be considered an alternative first choice option for the treatment and stable COPD?
72. Efficacy of salmeterol xinafoate in the treatment of COPD
73. Is theophylline obsolete?
74. Theophylline is no more obsolete than two puffs qid of current beta-2 agonists
75. Theophylline therapy. A continuing dilemma
76. A randomized controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease
77. Theophylline and mucocilliary function
78. Theophylline improves global cardiac function and reduces dyspnea in chronic obstructive lung disease
79. Effects of aminophylline on diaphragmatic fatigue during acute respiratory failure
80. Salmeterol versus slow-release theophylline in patients with reversible obstructive pulmonary disease
81. Use of theophylline in the treatment of COPD
82. Corticoides inhalados en la EPOC
83. EUROSCOP, ISOLDE and the Copenhagen city lung study
84. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial
85. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking
86. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease
87. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial
88. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis
89. Guidelines for the approach to the patient with severe hereditary alpha I-antitripsin deficiency
90. Estado actual del tratamiento sustitutivo en el enfisema congénito pot déficit de alfa-1-antitripsina. Informe del registro nacional
91. 1 decline in individuals with severe deficiency of alpha-1-antitrypsin
92. 1 in patients with severe hereditary alpha I-antitrypsin deficiency?
93. Clinical trials needed for alpha-1-antitrypsin replacement therapy
94. Chronic respiratory failure in COPD: Is there a place for a respiratory stimulant?
95. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published double-blind, placebo-controlled trials
96. Normativa sobre la rehabilitación respiratoria
97. Rehabilitación respiratoria
98. Pulmonary rehabilitation: Joing ACCP/AACVPR evidence-based guidelines
99. Rehabilitación respiratoria
100. Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale
101. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease
102. The longterm effects of pulmonary rehabilitation in patients with asthma and chronic obstructive pulmonary disease: A research synthesis. Meta-analysis
103. Muscle strength, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders
104. Peripheral muscle weakness contributes to exercise limitation in COPD
105. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease
106. Randomised controlled trial of weight-lifting exercise in patients with chronic airflow limitation
107. Aerobic and strength training in patients with chronic obstructive pulmonary disease
108. Comparación entre diferentes modalidades de entrenamiento muscular periférico en la rehabilitación de pacientes con EPOC estables
109. Respiratory muscle training in chronic airflow limitation: A meta-analysis
110. Inspiratory muscle training in chronic airflow limitation: Comparison of two different training loads using a threshold device
111. Entrenamiento de los músculos inspiratorios en la enfermedad pulmonar obstructiva crónica: Su repercusión en parámetros funcionales y tolerancia al ejercicio
112. Home ventilatory muscle training in patients with chronic obstructive pulmonary disease (COPD)
113. Nutritional support for individuals with COPD: A meta-analysis
114. Quality of life in patients with chronic obstructive pulmonary disease improves after rehabilitation in the home
115. A comparison between an outpatient hospital-based pulmonary rehabilitation program and a home-care rehabilitation program in patients with COPD
116. Home treatment of exarcerbations of chronic obstructive pulmonary disease by an acute respiratory assessment service
117. Randomised controlled trial comparing hospital at home care with inpatient hospital care. II: Cost minimisation analysis
118. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema
119. Continous or nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease: A clinical trial
120. Normativa para la indicación y empleo de la oxigenoterapia continua domiciliaria (OCD)
121. A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients
122. Travel for technology-dependent patients with respiratory disease
123. The Registry of the International Society for Heart and Lung Transplantation: Fifteenth official report-1998
124. Lung transplantation
125. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease
126. Comparison of outcomes of double and single lung transplantation for obstructive lung disease
127. Exercise performance after lung transplantation
128. Long-term health status and quality of life outcomes of lung transplant recipients
129. International guidelines for the selection of lung transplant candidates
130. Bilateral pneumectomy (volume reduction) for chronic obstructive pulmonary disease
131. Lung volume reduction surgery
132. Rationale and design of the National Emphysema Treatment Trial: A prospective randomized trial of lung volume reduction surgery
133. Effect of lung-volume-reduction surgery in patients with severe emphysema
134. Lung volume reduction surgery for emphysema
135. Lung function 4 years after lung volume reduction surgery for emphysema
136. Lung volume reduction surgery: Comparison of preoperative radiologic features and clinical outcome
137. Evaluation and preoperative management of lung volume reduction surgery candidates
138. Reduction pneumoplasty for giant bullous emphysema. Implications for surgical treatment of nonbullous emphysema
139. The physiologic evaluation of the lung resection cadidate
140. Functional evaluation of the lung resection candidate
141. Preoperative assessment as a predictor of mortality and morbility after lung resection
142. Invasive exercise testing in the evaluation of patients at high-risk for lung resection
143. Wedge resection versus lobectomy for stage I (T1 NO MO) non-small-cell lung cancer
144. Early postoperative stress: Video-assisted wedge resection/lobectomy vs conventional axillary thoracotomy
145. Exercise capacity as a predictor of postoperative complications in lung resection candidates
146. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation
147. Prospective study of aetiology and outcome of adult lower-respiratory tract infections in the community
148. Initial antibiotic therapy for lower respiratory tract infection in the community: A European survey
149. Association of indoor and outdoor particulate pollution level with chronic respiratory illness
150. The UCLA population studies of chronic obstructive pulmonary disease. XI. Impact of air pollution and smoking on annual change in forced expiratory volume in one second
151. Use of emergency medical services by patients with decompensated obstructive lung disease
152. When can an exacerbation of COPD be trated at home?
153. Dose-response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease
154. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease
155. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease
156. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis
157. Epidemiology and treatment of chronic bronchitis and its exacerbations
158. Controlled clinical trials of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency
159. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: A prospective randomised controlled trial
160. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease
161. Spirometric criteria for hospital admission of patients with acute exacerbation of COPD
162. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease
163. Outcomes following acute exacerbations of severe chronic obstructive lung disease
164. Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease
165. Oxygen therapy during exacerbations of chronic obstructive pulmonary disease
166. Central respiratory drive in acute respiratory failure of patients with chronic obstructive pulmonary disease
167. 2 on ventilation and blood gases in patients with chronic obstructive pulmonary disease during acute respiratory failure
168. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease
169. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease
170. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure
171. Non-invasive ventilatory support does not facilitate recovery from acute respiratory failure in chronic obstructive pulmonary disease
172. Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease. A randomized, controlled trial
173. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: A multicentre randomised controlled trial